Emerging cancer therapies and granulocyte-colony stimulating factor in febrile neutropenia patients presenting to the emergency department during the COVID-19 pandemic era

Am J Emerg Med. 2023 Jun:68:189-190. doi: 10.1016/j.ajem.2023.04.021. Epub 2023 Apr 18.

Authors

Wei-Jen Lai¹, Chen-Xiong Hsu²

Affiliations

¹ Division of Medical Imaging, Department of Radiology, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
² Division of Radiation Oncology, Department of Radiology, Far Eastern Memorial Hospital, New Taipei City, Taiwan; Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan. Electronic address: xc710077@gmail.com.

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Agents* / adverse effects
COVID-19*
Emergency Service, Hospital
Febrile Neutropenia* / drug therapy
Granulocyte Colony-Stimulating Factor / therapeutic use
Granulocytes
Humans
Neoplasms* / drug therapy
Neoplasms* / therapy
Pandemics

Substances

Granulocyte Colony-Stimulating Factor
Antineoplastic Agents